Search clinical trials for: Endocrinology; Hypercholesterolemia; Hyperlipidemia; Lipid Metabolism Disorders RN316 PF-04950615

Total 153674 results

Pfizer

Completed

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias

United States
Pfizer

Completed

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Hypercholesterolemia

United States
Pfizer

Completed

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Pfizer

Completed

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Dyslipidemia | Hypercholesterolemia

United States
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (SPIRE-SI)

Hyperlipidemia

United States, Canada
Pfizer

Completed

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia

United States
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Pfizer

Completed

A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Hypercholesterolemia

Japan
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Disease

Finland, United States, Netherlands, Spain, Korea, Republic of, China, Israel, Belgium, Germany, Australia, Czechia, Taiwan, Denmark, United Kingdom, Hungary, Poland, France, Mexico, Turkey, Canada, New Zealand, Colombia, Switzerland, Irelan... and more
Pfizer

Completed

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Hypercholesterolemia

United States
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)

Cardiovascular Disease

United States, Finland, Netherlands, Spain, Belgium, Germany, Czechia, Switzerland, Denmark, Australia, United Kingdom, Korea, Republic of, Hungary, Israel, Poland, Taiwan, Mexico, Turkey, Ireland, Canada, New Zealand, South Africa, Brazi... and more
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH)

Heterozygous Familial Hypercholesterolemia

Canada, Netherlands, United Kingdom, United States, Spain, Poland, Finland, Norway, South Africa, Italy, Bulgaria
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
University of California, San Francisco
Pfizer; San Francisco General Hospital

Terminated

Bococizumab HIV Evaluation (B-HIVE) Study (B-HIVE)

Cardiovascular Disease | Dyslipidemia

United States
Prince of Songkla University

Active, not recruiting

Gastric Volume After Ingestion of Carbohydrate Drink vs Water in Obese Volunteers

Obesity | Gastric Emptying

Thailand
Assiut University

Not yet recruiting

Intrapartum Ultrasonography in Evaluation of the Progress of Labor

Progress pf Labor
Children's Hospital of Philadelphia
National Library of Medicine (NLM)

Completed

Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants (PreemieCDS)

Prematurity

United States
Olympus Biotech Corporation

Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (TRANS-North)

Diabetic Foot Ulcer of Neuropathic Origin

Belgium, Germany, Poland, Croatia, Bulgaria, Denmark, Slovakia, Hungary, Netherlands, Sweden
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Pfizer
Halozyme Therapeutics

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Healthy | Hypercholesterolemia

Belgium
MTI University

Unknown

Triceps Taping on Elbow Flexion Tightness in Extended Erb's Palsy

Deformity Flexion

Egypt
Karen-Lise Garm Spindler
Zealand University Hospital; Vejle Hospital

Recruiting

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer (OPTIMISE)

Colorectal Cancer | Metastatic Cancer

Denmark
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Pfizer

Withdrawn

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects (SPIRE-ASIA)

Primary Hyperlipidemia or Mixed Dyslipidemia

China
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Seoul National University Hospital

Unknown

Predictive Model for Postoperative Complications in Hemi-hip Arthroplasty

Arthroplasty | Complication | Risk Factor | Elderly Patient

Korea, Republic of
Seoul National University Hospital

Recruiting

Registry for Degenerative Spinal Disease (RDSD) (RDSD)

Surgery | Degeneration Spine

Korea, Republic of
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
HaEmek Medical Center, Israel

Unknown

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Herpes Zoster

Israel
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Chung-Ang University Gwangmyeong Hospital

Not yet recruiting

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Neurologic Disorder
Medical University of Warsaw

Completed

Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.

Type 1 Diabetes Mellitus

Poland
Seoul National University Hospital

Unknown

The Recovery Profiles After Robotic or Open Thyroidectomy

Postoperative Pain | Postoperative Sorethroat

Korea, Republic of
Chinese PLA General Hospital
Gansu Provincial Maternity and Child-Care Hospital

Unknown

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision

MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision
Pfizer

Completed

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

Single Dose Study of PF-06815345 in Healthy Subjects

Hypercholesterolemia

Belgium

3

Subscribe